immuno-oncology: what is next for aml?
Published 3 years ago • 57 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
2:11
the current role of immuno-oncology in aml and future outlooks
-
2:09
eha: aml immuno-oncology updates
-
1:05
the future of immuno-oncology
-
1:29
the current landscape of immunotherapy for aml: an update from ash 2023
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
5:20
immuno-oncology agents for mm: checkpoint inhibitors and nk-cells
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
3:37
the future of aml treatment
-
15:35
ori bio
-
2:17
updates on the flt3 inhibitor ff-10101 for the treatment of r/r aml
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
1:55
diagnosing and treating aml: the role of mutational profiling
-
11:19
immunotherapy for aml & all
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
2:16
the challenges in producing efficacious i-o products for aml
-
1:11
the treatment of aml within the united kingdom nhs framework
-
3:10
novel aml treament approaches
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen
-
2:41
advancements in aml: an update from ash 2023
-
1:04
clad-ldac-ven induction therapy in aml: insights from a phase ii trial
-
2:57
exciting research in aml and important considerations for the future